[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$acads
Crypto project sees increased community engagement. Market volatility and competition are causing some concern among investors.
About $acads
A cryptocurrency project.
Insights #
- $acads engagements is up XXXXXX% from the previous month.
Engagements: XX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1 Week: XXX +105%
1 Month: XXX +109%
1-Year High: XX on 2025-10-04
1-Year Low: XX on 2025-09-03
| Social Network | X |
|---|---|
| Engagements | XX |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-10-04
1-Year Low: X on 2025-09-01
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $acads in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X
1-Year High: X on 2025-10-04
1-Year Low: X on 2025-09-01
The most influential creators that mention $acads in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Quantumup1 | X | XXXXX | X | XX |
Top assets mentioned In the posts about $acads in the last XX hours
Soleno Therapeutics, Inc. Common Stock (SLNO) Acadia Pharmaceuticals Inc. (ACAD) Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)
Top topics mentioned In the posts about $acads in the last XX hours
$slno, $acad, $slnos, $2b, $aard, $rytm, investment
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Stifel trimmed $SLNO's PT to $XXX from $XXX and reiterated at a Buy after refreshing its PWS model to reflect recent KOL feedbackStifel still sees pot'l $2B+ World-wide rev. oppy. $AARD $RYTM Stifel said in its note: Management remains confident in Vykat's safety and broader risk/benefit profile (i.e. consistent with data/label and known AE-profile) noting feedback from KOLs and patient advocacy groups is positive. Looking ahead management remains confident in the growth trajectory of Vykat even as naturally there's some element of a "bolus" here (2Q numbers can't be extrapolated linearly in"
X Link @Quantumup1 2025-10-01T11:51Z 3826 followers, 16.6K engagements
"@AngelineRa91784 @semodough @fans_crazy2 Absolutely quiet wins count just as much. In investing like with $ACAD's pipeline progress steady advances often pay off without fanfare. What's your take"
X Link @grok 2025-09-25T01:21Z 6.4M followers, XX engagements
"Stifel reiterated $SLNO at Buy-$118 and said $ACAD announced ACP-101's ph3 trial in Prader-Willi failed. In light of some of the noise around Vykat's safety $ACAD's readout (even as we think most were skeptical) had become a meaningful overhang for the stock. The setup into these data in the backdrop of headline risk questions about potential near-term M&A etc. we think collectively was a major driver for the pressure on the stock (vs. a complete/fundamental reset on peak sales). As such this should be a nice clearing event for the stock and allow shares to work again into 3Q EPS where with a"
X Link @Quantumup1 2025-09-24T11:57Z 3826 followers, 10.4K engagements